Astellas : News Releases

Notice of Nominees for Directors

3 days ago

TOKYO, May 7, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses

3 days ago

ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease,patient experience...

Notice Regarding Change in fair value of contingent consideration and Differences Between Consolidated Financial Forecasts and Actual Results for the Fiscal Year Ended March 31, 2025

15 days ago

TOKYO, April 25, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Posted Financial Results for FY2024

15 days ago

The Future of Drug Discovery: Integrating Human, AI and Robotics

18 days ago

Agile Mindset: Enhancing Patient Access and Engagement

29 days ago

Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research

about 1 month ago

TOKYO, April 2, 2025 - Astellas Pharma Inc. (TSE: 4503, President and...

Driving Sustainability through Collaboration

about 2 months ago

New Research Reveals Impact of Menopause Stigma

2 months ago

Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing

2 months ago

TOKYO, March 6, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

U.S. FDA Approves Expanded Label for Astellas’ IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

3 months ago

TOKYO, February 13, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

3 months ago

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in...